Stay updated with breaking news from Affimed. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
HC Wainwright reissued their buy rating on shares of Affimed (NASDAQ:AFMD – Get Rating) in a report published on Friday morning, Benzinga reports. The brokerage currently has a $6.00 target price on the biopharmaceutical company’s stock. AFMD has been the topic of several other research reports. SVB Leerink decreased their price objective on Affimed from […]
Affimed (NASDAQ:AFMD – Get Rating) had its price objective cut by equities researchers at Stifel Nicolaus from $2.00 to $1.00 in a research report issued to clients and investors on Friday, The Fly reports. The brokerage currently has a “hold” rating on the biopharmaceutical company’s stock. Stifel Nicolaus’ target price would suggest a potential upside […]
Investment Analysts’ downgrades for Friday, March 24th: Affimed (NASDAQ:AFMD) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. Berkshire Hills Bancorp (NYSE:BHLB) was downgraded by analysts at StockNews.com from a hold rating to a sell rating. Bruker (NASDAQ:BRKR) was downgraded by analysts at StockNews.com from a strong-buy rating to a […]
Stock Analysts’ price target changes for Friday, March 24th: AirBoss of America (OTCMKTS:ABSSF) had its price target lowered by TD Securities from C$14.00 to C$11.50. Accolade (NASDAQ:ACCD) had its target price raised by Truist Financial Co. to $17.00. Accenture (NYSE:ACN) had its price target boosted by Citigroup Inc. from $300.00 to $310.00. Citigroup Inc. currently […]
HEIDELBERG, Germany, Aug. 04, 2022 -- Affimed N.V. , a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer, announced today that it will... | August 4, 2022